Single Site, Open Label Pilot Study of PRX-03140 to Assess Safety for Use in Adult Subjects With Post Traumatic Stress Disorder.
Phase of Trial: Phase II
Latest Information Update: 02 Oct 2017
At a glance
- Drugs PRX 3140 (Primary)
- Indications Post-traumatic stress disorders
- Focus Adverse reactions
- Sponsors Nanotherapeutics; Ology Bioservices
- 02 Oct 2017 According to a Ology Bioservices media release, Nanotherapeutics changed its name to Ology Bioservices.
- 01 Jun 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jan 2013 Planned End Date changed from 1 Dec 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.